Trinity Biotech Faces Nasdaq Listing Risk Due to Public Float Deficiency.

Trinity Biotech received a notice from Nasdaq on February 19, 2026, stating that it no longer complies with the minimum market value of publicly held shares requirement. The deficiency relates to Nasdaq's rule requiring a minimum of $15M public float for continued listing. Trinity Biotech must submit a plan to regain compliance within 45 days or face delisting.